Invasive fungal infections in liver transplant recipients receiving tacrolimus as the primary immunosuppressive agent

Clinical Infectious Diseases

Volumn 24, Issue 2, 1997, Pages 179-184

  Singh, Nina ^a,b   Gayowski, Timothy ^a   Wagener, Marilyn M ^a   Doyle, Howard ^a   Marino, Ignazio R ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b VA Healthcare VISN 4   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; AZATHIOPRINE; AZTREONAM; CLINDAMYCIN; COLISTIN; COTRIMOXAZOLE; CYCLOSPORIN; GANCICLOVIR; GENTAMICIN; NYSTATIN; TACROLIMUS;

ADULT; ARTICLE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION RISK; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MYCOSIS; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RISK ASSESSMENT;

EID: 0031043279     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinids/24.2.179     Document Type: Article

References (22)

1. Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994; 170:644-52.
2. Kusne S, Dummer JS, Singh N, et al. Infections after liver transplantation: an analysis of 101 consecutive cases. Medicine 1988;67:132-43.
3. Briegel J, Forst H, Spill B, et al. Risk factors for systemic fungal infections in liver transplant recipients. Eur J Clin Microbiol Infect Dis 1995; 14: 375-82.
4. Wade JJ, Rolando N, Hayllar K, Philpott-Howard J, Casewell MW, Williams R. Bacterial and fungal infections after liver transplantation: an analysis of 284 patients. Hepatology 1995;21:1328-36.
5. Mora NP, Klintmalm G, Solomon H, Goldstein RM, Gonwa TA, Husberg BS. Selective amphotericin B prophylaxis in reduction of fungal infections after liver transplant. Transplant Proc 1992;24:154-5.
6. Castaldo P, Stratta RJ, Wood RP, et al. Clinical spectrum of fungal infections after orthotopic liver transplantation. Arch Surg 1991; 126: 149-56.
7. Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993; 16:677-88.
8. Harding MW, Galat A, Uehling DE, Schreiber SL. A receptor for the immunosuppressant FK506 in a cis-trans peptidyl-prolyl isomerase. Nature 1989;341:758-60.
9. Ochiai T, Nakajima K, Nagata M, et al. Effect of a new immunosuppressive agent, FK506, on heterotropic cardiac allotransplantation in the rat. Transplant Proc 1987; 19:1284-6.
10. The U.S. Multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994;331:1110-5.
11. Singh N, Yu VL, Mieles L, Wagener MM, Miner RC, Gayowski T. High dose acyclovir versus short-course preemptive ganciclovir therapy to prevent cytomegalovirus disease in liver transplant recipients: a randomized trial. Ann Intern Med 1994; 120:375-81.
12. Schröter GPJ, Hoelscher M, Putnam CW, Porter KA, Starzl TE. Fungus infections after liver transplantation. Ann Surg 1977; 186:115-22.
13. Wajszczuk CL, Dummer JS, Ho M, et al. Fungal infections in liver transplant recipients. Transplantation 1985;40:347-53.
14. Hadley S, Samore MH, Lewis WD, Jenkins RL, Karchmer AW, Hammer SM. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 1995; 59: 851-9.
15. Consensus Development Conference Panel. Morbidity and mortality of renal dialysis: an NIH consensus conference statement. Ann Intern Med 1994; 121:62-70.
16. Kusne S, Torre-Cisneros J, Mañez R, et al. Factors associated with invasive lung aspergillosis and significance of positive Aspergillus culture after liver transplantation. J Infect Dis 1992; 166:1379-83.
17. LaQuaglia MP, Tolkoff-Rubin NE, Dienstag LE, et al. Impact of hepatitis on renal transplantation. Transplantation 1981;32:504-7.
18. Singh N, Mieles L, Yu VL, Gayowski T. Invasive aspergillosis in liver transplant recipients: association with candidemia and consumption coagulopathy and failure of prophylaxis with low-dose amphotericin B. Clin Infect Dis 1993; 17:906-8.
19. Tollemar J, Höckerstedt K, Ericzon BG, Jalanko H, Ringdén O. Liposomal amphotericin B prevents invasive fungal infections in liver transplant recipients. Transplantation 1995;59:45-50.
20. Goldman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992;326:845-51.
21. Slavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation - a prospective, randomized, double-blind study. J Infect Dis 1995; 171:1545-52.
22. Nguyen MH, Peacock JE, Morris AJ, et al. The changing face of candidemia: emergence of non-Candida albicans species and antifungal resistance. Am J Med 1996; 100:617-23.